quinupristin

quinupristin

 [kwin-u´pris-tin]
a semisynthetic antibacterial effective against a variety of gram-positive organisms. It is used in conjunction with dalfopristin in the treatment of serious bacteremia caused by vancomycin-resistant Enterococcus faecium and complicated skin and skin structure infections caused by Streptococcus pyogenes or methicillin-sensitive Staphylococcus aureus; administered intravenously.

quinupristin

/quin·u·pris·tin/ (kwin-u´pris-tin) a semisynthetic antibacterial used in conjunction with dalfopristin against various gram-positive organisms, including vancomycin-resistant Enterococcus faecium.

quinupristin

[kwinu′pris-tin]
a semisynthetic antibacterial effective against a variety of gram-positive organisms. It is used in conjunction with dalfopristin in the treatment of serious bacteremia caused by vancomycin-resistant Enterococcus faecium and complicated skin and skin structure infections caused by Streptococcus pyogenes or methicillin-sensitive Staphylococcus aureus. It is administered intravenously.

quinupristin

See Synercid®.
References in periodicals archive ?
5-8 [micro]g/ mL), tetracycline (1-32 [micro]g/mL), quinupristin (0.
For patients who have recently suffered from infection with vancomycin resistant Enterococcus (VRE) or MRSA, prophylaxis with linzolid, or quinupristin / dalfopristin can be considered.
b) Dalfopristin is combined with quinupristin in the same product.
Based on the Naranjo probability scale, the likelihood that quinupristin dalfopristin caused the anemia and reticulocytopenia is probable.
Treatment of methicillin - resistant Staphylococcus aureus infections with quinupristin - dalfopristin in patients intolerant of or failing prior therapy.
These drugs are streptogamins which contain two component types, A and B, which are represented by dalfoprisitin and quinupristin respectively.
Overall, 12 (50%) of 24 of the VRE samples had high levels of gentamicin resistance, 3 (12%) of 25 were resistant to quinupristin (Synercid), 13 (54%) of 24 were resistant to tetracycline, and 20 (83%) of 24 were resistant to penicillin.
Although, as a streptogramin B, quinupristin is cross-resistant with macrolides and lincosamides, dalfopristin is a streptogramin A and not part of this resistance pattern.
It is a novel, injectable antibiotic made of two molecules: quinupristin and dalfopristin.
Synercid[R] is a medication composed of two components, quinupristin and dalfopristin, and is available as an injectable solution.
All of the Enterococcus faecalis isolates were resistant to Quinupristin & Dalfopristin whereas isolated Enterococcus faecium were sensitive to those antimicrobials.